


edited by
Christian Weber
Oliver Soehnlein

ATHEROSCLEROSIS

Treatment and Prevention





ATHEROSCLEROSIS

edited by
Christian Weber
Oliver Soehnlein

ATHEROSCLEROSIS

Treatment and Prevention

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com

Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Atherosclerosis: Treatment and Prevention

Copyright © 2013 by Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4316-26-2 (Hardcover)

ISBN 978-981-4364-26-3 (eBook)

Printed in the USA

Contents

1. Chemokines and Their Receptors as Therapeutic Targets in Atherosclerosis	1
<i>Rory R. Koenen and Christian Weber</i>	
1.1 Introduction	1
1.2 Chemokines: Crucial Regulators of Leukocyte Trafficking	3
1.2.1 Structure and Function of Chemokines	3
1.2.1.1 Chemokine classification	3
1.2.1.2 Chemokine oligomerization and binding to glycosaminoglycans	4
1.2.1.3 Formation of heteromeric chemokine complexes	5
1.2.2 Mechanisms of Chemokine Action	6
1.2.2.1 Regulation of leukocyte trafficking by chemokines	6
1.2.2.2 Transportation and clearance of chemokines in tissues	7
1.3 The Chemokine System in Atherogenesis	8
1.3.1 Platelet Chemokines	8
1.3.2 Chemokines in the Progression and Regression of Atherosclerosis	9
1.3.2.1 Phase and cell type-specific function of chemokines	9
1.3.2.2 Combined blockade of chemokines	11
1.3.2.3 Role of chemokines in plaque regression	12
1.4 Therapeutic Targeting of the Chemokine System	13
1.5 Concluding Remarks	18
2. MIF Antagonism as a Therapeutic Approach to Atherosclerosis	31
<i>J. Bernhagen and A. Schober</i>	
2.1 Introduction	32
2.2 Biochemical and Structural Properties of MIF	33

2.3	MIF Expression and Secretion: Mechanism and Occurrence in Disease	34
2.4	MIF Receptors and Molecular Determinants of MIF Action	35
2.5	MIF Expression in Atherosclerotic Plaque	38
2.6	Role of MIF in Atherogenesis	39
2.7	Epidemiologic Correlations Between MIF and Cardiovascular Disease	40
2.8	Pro-Atherogenic MIF Mechanisms	41
2.9	MIF Acts as a Functional Chemokine in Atherosclerosis	42
2.10	CLF Chemokines in Atherosclerosis	45
2.11	Therapeutic Approaches to Target MIF in Inflammation and Atherosclerosis	46
2.11.1	Targeting the Non-Conventional Secretion of MIF	47
2.11.2	Targeting the Unique Structural Characteristics and MIF/MIF Receptor Interactions	49
2.11.3	Targeting the Evolutionarily Conserved Catalytic Sites of MIF	50
2.12	Concluding Remarks	52
3.	Peptide-Based Vaccination Strategies to Promote Treg-Mediated Atheroprotection	65
	<i>Hafid Ait-Oufella, Olivier Herbin, Alain Tedgui, and Ziad Mallat</i>	
3.1	Regulatory T cells Maintain Self-Tolerance	66
3.2	Two Major Mediators of Treg Cell Function with Relevance to Atherosclerosis: TGF- β and IL-10	68
3.2.1	TGF- β	68
3.2.1.1	TGF- β and Treg cell function	68
3.2.1.2	Role of T cell-dependent TGF- β in atherosclerosis	70
3.2.2	IL-10	71
3.2.2.1	IL-10 and Treg cell function	71
3.2.2.2	Role of IL-10 in atherosclerosis	72
3.3	Strategies to Enhance Treg Function in Atherosclerosis	73

3.3.1	Strategies to Promote CD4 ⁺ CD25 ⁺ Foxp3 ⁺ Treg Cell Function <i>in vivo</i>	73
3.3.2	Strategies to Promote Foxp3-Independent Regulatory T Cell Response	76
3.4	Conclusion	78
4.	Eicosanoids in Atherosclerosis	85
	<i>Antonio Di Gennaro, Min Wan, M. Dolores Salvado, Jia Sun, and Jesper Z. Haeggström</i>	
4.1	Introduction	85
4.2	Prostanoids and Atherosclerosis	87
4.3	Leukotrienes and Atherosclerosis: Key Biosynthetic Enzymes	90
4.3.1	5-LOX	91
4.3.2	FLAP	93
4.3.3	LTA ₄ H	94
4.3.4	LTC ₄ S	95
4.4	Leukotrienes and Atherosclerosis: Leukotriene Receptors	96
4.4.1	LTB ₄ and BLT Receptor-Induced Immune Responses	98
4.4.2	LTB ₄ and BLT Receptor-Induced Vascular Responses	100
4.4.3	LTB ₄ and BLT Receptors in Plaque Instability	101
4.4.4	Cysteinyl-LTs and CysLT Receptors in Atherogenesis	101
4.4.5	LTs and Atherosclerosis: Summary	102
4.5	12/15-Lipoxygenase and Atherosclerosis	103
5.	Stabilization of Mast Cells for Taming Vulnerable Plaques	123
	<i>Guo-Ping Shi and Peter Libby</i>	
5.1	Introduction	123
5.2	Mast Cells in Atherosclerotic Lesions	127
5.2.1	Mast Cell Location and Recruitment in Atherosclerotic Lesions	127
5.2.2	Clinical Evidence of Mast Cell Involvement in Atherosclerosis	128

5.3	Mast Cell Functions and Atherosclerosis	129
5.3.1	Mast Cell Activation	129
5.3.2	Mast Cells Modulate Vascular Cell Growth and Apoptosis	132
5.3.3	Mast Cell Function in Atherosclerotic Lesion Neovascularization	134
5.3.4	Mast Cells in Foam-Cell Formation	135
5.3.5	MC Products Can Promote the Activation of Protein Mediators by Limited Proteolysis	136
5.4	MC Functions in Experimental Atherosclerosis	137
5.4.1	Proof of Concept in Experimental Atherosclerosis	138
5.4.2	MC Activation or Stabilization in Experimental Atherosclerosis	140
5.5	MC Chymase and Trypsin in Atherosclerosis	142
5.5.1	Chymases and Trypsins in Atherosclerosis	142
5.5.2	Chymase and Trypsin Inhibitors in Atherosclerosis	143
5.5.3	Chymase Inhibitors in Myocardial Infarction	144
5.6	Clinical Implications of MC and MC Mediator Inhibitors	145
5.7	Conclusion	147
6.	HDL, ABC Transporters, and Cholesterol Efflux as Therapeutic Targets in Atherosclerosis	169
	<i>Kazuhiro Nakaya, Katsunori Ikewaki, and Daniel J. Rader</i>	
6.1	Introduction	170
6.2	The Role of ABC Transporters, and the Nature and Quantity of Extracellular HDL-Based Acceptors in Macrophage Cholesterol Efflux	172
6.3	Therapeutic Strategies for Increasing Macrophage Cholesterol Efflux	174
6.4	Therapeutic Strategies for Improving Quantity and Functionality of HDL-Based Acceptors	175
6.5	Conclusion	178

7. Role of Selective Phospholipase A₂ Inhibition in the Treatment of Atherosclerosis 185

Colin H. Macphee

7.1 Introduction	185
7.2 Secreted PLA ₂ s: Targets for Intervention	186
7.3 Substrates Preferences, Lipoprotein Metabolism, and Activity Against Pathogens	188
7.3.1 Lp-PLA ₂	188
7.3.2 sPLA ₂	191
7.4 Cellular Sources, Expression Within Vulnerable Plaque and Genetically Altered Mouse Studies	193
7.4.1 Lp-PLA ₂	193
7.4.2 sPLA ₂	194
7.5 Human Epidemiology and Genetics	196
7.5.1 Lp-PLA ₂	196
7.5.2 sPLA ₂	197
7.6 Pharmacological Intervention: Darapladib	198
7.6.1 Animal Model	198
7.6.2 Clinic	199
7.7 Pharmacological Intervention: Varespladib	200
7.7.1 Animal Model	200
7.7.2 Clinic	200
7.8 Summary	202

8. The Renin Angiotensin System in Atherosclerosis 217

Hong Lu, Lisa A. Cassis, and Alan Daugherty

8.1 Introduction	217
8.2 The Renin Angiotensin System	218
8.3 Regulation of Experimental Atherosclerosis by the RAS	219
8.3.1 AngII Infusions	220
8.3.2 Pharmacological RAS Inhibition	220
8.3.2.1 Angiotensin-converting enzyme inhibition	220
8.3.2.2 AngII receptor antagonists	222
8.3.2.3 Renin inhibition	223
8.4 Genetic Manipulation of the RAS	223
8.4.1 Angiotensin Receptors	224
8.4.2 Angiotensin-Converting Enzyme	224

8.4.3	ACE2	225
8.4.4	Angiotensinogen and Renin	225
8.5	Potential Mechanisms of RAS Modulating Atherosclerosis	226
8.5.1	Hypercholesterolemia Activates the RAS	226
8.5.2	Systemic versus Local Synthesis of Angiotensin Peptides	227
8.5.3	Angiotensin Peptide Effects on Cells in Atherosclerosis	228
8.5.3.1.	Endothelial dysfunction and monocyte adhesion	228
8.5.3.2	Macrophage recruitment and vascular inflammation	229
8.5.3.3	Smooth muscle cell proliferation	230
8.5.3.4	Thrombosis	230
8.6	Clinical Indication of RAS in Atherosclerosis	231
8.6.1	RAS Components Are Present in Human Atherosclerotic Lesions	231
8.6.2	RAS Inhibition Reduces Atherosclerosis-Related Cardiovascular Events	231
8.6.3	Genetic Studies of RAS Components in Human Atherosclerotic Disease	233
8.7	Conclusions	235
9.	Role of Matrix Metalloproteinases as Targets for the Prevention of Atherosclerosis	255
	<i>Andrew C. Newby</i>	
9.1	Key Role of Extracellular Proteolysis at all Stages of Atherosclerosis	255
9.2	Characteristics of the MMP Family	256
9.3	Regulation of MMP Activity in Vascular Cells	260
9.4	Functional Effects of MMPs and TIMPs	266
9.4.1	Endothelial Cells	266
9.4.2	Vascular Smooth Muscle Cells	266
9.4.3	Monocytes and Macrophages	268
9.5	Genetic Manipulation of MMPs and TIMPs in Experimental Models of Atherosclerosis	269
9.6	MMPs and TIMPs in Human Atherosclerotic Plaques	273

9.7 Inhibition of MMPs as Therapy for Atherosclerosis or Plaque Disruption	273
10. Probucol-Derivatives in the Treatment of Atherosclerosis	285
<i>Robyn G. Midwinter and Roland Stocker</i>	
10.1 Introduction	285
10.2 Probucol and Atherosclerosis	286
10.2.1 Anti-Atherosclerotic Effects of Probucol	286
10.2.2 Probucol's Mode of Action	287
10.2.2.1 Anti-inflammatory activity	287
10.2.2.2 Anti-oxidant activity	287
10.2.2.3 Induction of heme oxygenase-1	288
10.3 Analogues of Probucol	289
10.3.1 Succinobucol	289
10.3.1.1 Succinobucol as an anti-inflammatory	289
10.3.1.2 Succinobucol as an anti-oxidant	290
10.3.1.3 Heme oxygenase-1 and succinobucol	290
10.3.1.4 Succinobucol in pre-clinical studies	291
10.3.1.5 Succinobucol clinical trials	291
10.3.1.6 Safety of succinobucol	293
10.4 Other Probucol Derivatives	293
10.5 Conclusion	294
11. Interference with ER Stress and Restoration of Efferocytosis in the Treatment of Advanced Atherosclerosis	299
<i>Edward Thorp, Lale Ozcan, and Ira Tabas</i>	
11.1 Overview of ER Stress and Efferocytosis in Atherosclerosis	299
11.2 Part I. ER Stress Therapy	300
11.2.1 Introduction to ER Stress in Atherosclerosis	300
11.2.2 Candidate Targets for ER Stress Therapy in Advanced Lesions	303

11.2.2.1	Targeting macrophage apoptosis	303
11.2.2.2	Targeting endothelial cells	306
11.2.2.3	Targeting vascular smooth muscle cells	307
11.2.2.4	Targeting oxidative stress	308
11.2.3	Metabolic Risk Factors	308
11.3	Part II. Efferocytosis Therapy: Targeting Defective Efferocytosis in the Treatment of Advanced Atherosclerotic Plaque	311
11.3.1	Introduction to Defective Efferocytosis in Advanced Atherosclerosis	311
11.3.2	Candidate Efferocytosis Targets and Interventions	312
11.3.2.1	Alleviating cellular stress during clearance	312
11.3.3	Inflammatory Phagocyte Recruitment, Polarization, and Resolution	314
11.3.3.1	Targeting and repairing the phagocytic synapse	316
11.3.3.2	Metabolic risk factors and nuclear receptors	318
11.3.4	Potential Biomarkers of Defective Efferocytosis	319
11.4	Conclusions and Future Directions of ER Stress and Efferocytosis Therapy	319
12.	MicroRNAs in the Pathogenesis and Therapy of Atherosclerotic Vascular Disease	341
	<i>Andreas Schober and Mihail Hristov</i>	
12.1	Introduction	341
12.2	MicroRNAs: Biogenesis and Function	342
12.3	miRs Drive Smooth Muscle Cell Function in Atherosclerosis	344
12.4	miRs Modulate Endothelial Function in Atherosclerosis	347
12.5	miRs in Atherogenic Macrophage Function	349
12.6	miR in Angiogenesis and Cardiovascular Medicine	353
12.7	Concluding Remarks	354

13. Neutrophilic Granulocytes in the Treatment of Atherosclerosis	365
<i>Oliver Soehnlein and Christian Weber</i>	
13.1 Neutrophils Contribute to Atherosclerosis: Evidence from Human and Murine Studies	366
13.2 Potential Mechanisms of Neutrophil-Mediated Atherosclerosis and Means of Interference	367
13.3 Neutrophil Priming and Induction of Neutrophilia by Hypercholesterolemia	367
13.4 Neutrophil Recruitment in Atherosclerosis	371
13.5 Monocyte and Macrophage Activation by PMN Granule Proteins	373
13.6 Production of Reactive Oxygen Species	376
13.7 Concluding Remarks	379
14. Platelets as Therapeutic Targets of Atherosclerosis	393
<i>Dirk Lievens and Philipp von Hundelshausen</i>	
14.1 Introduction	393
14.2 Mechanisms of Thrombus Formation	394
14.3 Established Platelet Activation/Aggregation Inhibitors	395
14.3.1 Aspirin	395
14.3.2 ADP Receptor Blockers	397
14.3.3 Integrin α IIb β 3 Inhibitors	400
14.3.4 Signaling Inhibitors: The Phodiesterase Inhibitors Cilostazol and Dipyridamole	401
14.4 New Developments	403
14.4.1 Direct Thromboxane A2 Receptor Antagonists	403
14.4.2 Thrombin Receptor Antagonists	404
14.4.3 VWF Antagonists	405
14.4.4 GPIIb/IIIa Antagonists	406
14.4.5 Serotonin Receptor Antagonists	407
14.4.6 GPVI Antagonists	408
14.5 Platelets in Inflammation	409
14.5.1 Inflammatory Surface Molecules	410
14.5.1.1 P-selectin and PSGL-1	411
14.5.1.2 CD40-CD40L	412
14.5.1.3 Toll-like receptors	414
14.5.1.4 Chemokine receptors	415

14.5.2 Released Inflammatory Mediators	416
14.5.1.5 Junctional adhesion molecules	417
14.5.2.1 Chemokines	417
14.5.2.2 Cytokines	419
14.6 Conclusion	421
15. Co-stimulatory Molecules in Atherosclerosis	441
<i>Norbert Gerdes and Esther Lutgens</i>	
15.1 Introduction	441
15.2 The B7-Family	443
15.2.1 B7.1/2- CD28/CTLA4	443
15.2.2 ICOS-ICOSL	445
15.2.3 PD-PDL1/2	445
15.3 The TNF-TNF-Receptor Superfamily	446
15.3.1 OX40L-OX40	446
15.3.2 CD40L-CD40	447
15.3.3 CD137-CD137L	449
15.3.4 CD70-CD27	450
15.3.5 GITR/GITRL	450
15.3.6 LIGHT	451
15.4 TRAF Signaling	452
15.4.1 CD40-TRAF Signaling in Cardiovascular Disease	453
15.5 Conclusion	454
15.6 Perspectives	455
<i>Index</i>	467

Preface

Despite all innovations in prevention, diagnosis, and treatment, cardiovascular diseases as a consequence of atherosclerosis remain the leading cause for mortality and morbidity in industrial countries. Traditionally, atherosclerosis was attributed to progressive narrowing of the artery lumen owing to hyperlipidemia. It is now clear that the vascular wall is a site of chronic inflammation, resulting from complex interactions between the environment and the genetic make-up of the host. Over the past years, a tremendous number of preclinical studies have revealed novel aspects of the disease pathophysiology, and the feasibility of translating such knowledge to novel therapeutic approaches is currently being explored at various levels. This volume builds a bridge between the various aspects of recent advances of our understanding of the disease mechanisms underlying atherosclerosis and atherothrombosis and possible clinical applications that might derive from there.

Christian Weber

Oliver Soehnlein

Winter 2012

